8-KEarnings & ResultsOther EventsExhibits & Filings

QUEST DIAGNOSTICS INC 8-K Report, Financial Results (Oct 20, 2010)

Filed October 20, 2010For Securities:DGX

Summary

Quest Diagnostics Incorporated (DGX) filed an 8-K on October 20, 2010, primarily to announce its financial results for the quarter ended September 30, 2010, and a significant share repurchase authorization. The company's performance for the third quarter of 2010 was detailed in a press release, providing investors with updates on operational and financial conditions during that period. While the specific financial figures are not detailed within the 8-K itself, the filing indicates that these results were made public on the reporting date. In addition to the quarterly results, Quest Diagnostics' Board of Directors authorized a substantial $250 million share repurchase program. This move signals management's confidence in the company's valuation and its commitment to returning capital to shareholders. Investors should review the referenced press releases to understand the specific financial performance and the strategic implications of the accelerated share buyback, which can impact earnings per share and shareholder value.

Key Highlights

  • 1Quest Diagnostics reported its financial results for the quarter ended September 30, 2010, via a press release.
  • 2The company's Board of Directors authorized a $250 million share repurchase program.
  • 3The 8-K filing incorporates by reference two press releases detailing these announcements.
  • 4The filing indicates the date of these announcements was October 20, 2010.
  • 5The share repurchase program demonstrates a commitment to returning capital to shareholders.
  • 6Investors can refer to Exhibit 99.1 for Q3 2010 financial performance details.
  • 7Exhibit 99.2 provides further information on the share buyback authorization.

Frequently Asked Questions

The 8-K filing announces that Quest Diagnostics released its Q3 2010 financial results on October 20, 2010. The specific details are available in the press release incorporated by reference as Exhibit 99.1.

The authorization of a $250 million share repurchase program indicates that Quest Diagnostics' Board of Directors believes the company's stock is undervalued and plans to return capital to shareholders by buying back its own shares. This can potentially increase earnings per share and shareholder value.

More detailed information can be found in the two press releases that are incorporated by reference in this 8-K filing. Exhibit 99.1 contains the financial results for the quarter ended September 30, 2010, and Exhibit 99.2 details the share repurchase authorization.

Robert A. Hagemann is the Senior Vice President and Chief Financial Officer of Quest Diagnostics Incorporated, and he signed this 8-K filing on behalf of the company.